VEGFA and rheumatoid arthritis: Inhibiting vascular endothelial growth factor (VEGF) receptors and kinases, key targets of antiangiogenetic drugs in the context of cancer, have been considered for use in RA and attenuate the development pain behaviors in RA rodent models [81, 82].